Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation

  • Inga Buchmann
Part of the Medical Radiology book series (MEDRAD)


High dose radio-/chemotherapy in the context of autologous and allogeneic hematopoietic stem cell transplantation is a double-edged sword. The requirement for dose intensification is linked to an increase in toxicity to noninvolved organs. Particularly for older and co-morbid patients, efficient but toxicity-reduced schemes are needed. Myeloablative radioimmunotherapy is a targeted, internal radiotherapy that uses radio-labeled monoclonal antibodies (mAb) with affinity to the bone marrow. It applies high radiation doses up to 30 Gy into the bone marrow and spleen, but omits radio-sensitive organs to doses higher than 1–7 Gy. Added to conventional or intensity-reduced conditioning, myeloablative radioimmunotherapy may achieve a pronounced antileukemic effect with tolerable toxicities. A rational and individual design of the ideal nuclide-antibody combination optimizes therapy. The anti-CD33-, -CD45-, and -CD66-mAb appear to be ideal tracers so far. The [beta]Yttrium-90 is coupled by DTPA and is the most qualified nuclide for myeloablation. Approval trials for DTPA-anti-CD66-mAb are on the way in Europe and these therapies may become practically applicable in perspective.


Multiple Myeloma Acute Myeloid Leukemia Stem Cell Transplantation Chronic Myeloid Leukemia Autologous Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Attal M et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335(2):91–97PubMedCrossRefGoogle Scholar
  2. Barlogie B et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929–936PubMedCrossRefGoogle Scholar
  3. Behr M et al. (2002) High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 94(4suppl):1363–1372Google Scholar
  4. Blaise D et al (2007) Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukaemia. Haematologica 92:533–541PubMedCrossRefGoogle Scholar
  5. Boiron JM et al (2001) Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients. Leuk Lymphoma 41:285–296PubMedCrossRefGoogle Scholar
  6. Buchmann I et al (2002a) Myeloablative radioimmunotherapy with Re-188-anti-CD66-Antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation. Cancer Biother Radiopharm 17:151–163PubMedCrossRefGoogle Scholar
  7. Buchmann I et al (2002b) Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb before stem cell transplantation does not increase cytokine levels (abstract). J Nucl Med 43(suppl):314PGoogle Scholar
  8. Buchmann I et al (2002c) Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb in paediatric leukaemia patients: a phase I-trial. J Nucl Med 43(suppl):37PGoogle Scholar
  9. Buchmann I et al (2003) A comparison of biodistribution and biokinetics of 99mTc-anti-CD66-mAb BW250/183 and 99mTc-anti-CD45-mAb YTH24.5 with regard to suitability for myeloablative radioimmunotherapy. Eur J Nucl Med Mol Imaging 30:667–673PubMedCrossRefGoogle Scholar
  10. Buchmann I et al (2002) Myeloablative radioimmunotherapy with Re-188-anti-CD66-Antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation. Cancer Biother Radiopharm 17:151–163Google Scholar
  11. Bunjes D (2002) Re-188-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 43:2125–2131PubMedCrossRefGoogle Scholar
  12. Bunjes D et al (2001) Re-188-labeled anti-CD 66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98:565–572PubMedCrossRefGoogle Scholar
  13. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG (2003) Bone Marrow Transplant 32(6):549–556Google Scholar
  14. Camera L et al (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35(5):882–889PubMedGoogle Scholar
  15. Chaidos et al (2007) Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol 20(2):125–154CrossRefGoogle Scholar
  16. Child JA et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883PubMedCrossRefGoogle Scholar
  17. Clift RA et al (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimen. Blood 76:1867–1871PubMedGoogle Scholar
  18. Copelan EA (2006) Haematopoietic stem cell transplantation. New Engl J 354:1813–1826CrossRefGoogle Scholar
  19. Ferrara JL, Reddy P (2006) Pathophysiology of graft-versus-host disease. Semin Hematol 43(1):3–10PubMedCrossRefGoogle Scholar
  20. Frilling A et al (2006) Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140:968–976PubMedCrossRefGoogle Scholar
  21. Glatting G et al (2006) Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted radioimmunotherapy for acute leukemia. J Nucl Med 47:1335–1341PubMedGoogle Scholar
  22. Goldstone AH et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111(4):1827–1833PubMedCrossRefGoogle Scholar
  23. Hill GR et al (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 8:3204–3213Google Scholar
  24. Holler E et al (1995) Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 86:890–899PubMedGoogle Scholar
  25. Jurcic JG (2001) Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol 38:37–45PubMedCrossRefGoogle Scholar
  26. Jurcic JG et al (1995) Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 55(suppl):5908–5910Google Scholar
  27. Jurcic JG et al (2002) Targeted α-particle immunotherapy for myeloid leukemia. Blood 100:1233–1239PubMedGoogle Scholar
  28. Kottaridis PD et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98(6):1752–1759PubMedCrossRefGoogle Scholar
  29. Kröger N et al (2003) Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82(6):336–342PubMedCrossRefGoogle Scholar
  30. Kröger N (2007) Mini-Midi-Maxi? How to harness the graft-versus myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 21:1851–1858PubMedCrossRefGoogle Scholar
  31. Levine JE et al (2003) Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignany. Biol Blood Marrow Transplant 9:189–197PubMedCrossRefGoogle Scholar
  32. Loevinger R, Berman MA (1976) A revised schema for calculating the absorbed dose from biologically distributed radionuclides. Society of Nuclear Medicine, New York MIRD Pamphlet No1Google Scholar
  33. Martino R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108(3):836–846PubMedCrossRefGoogle Scholar
  34. Matsui W et al (2004) Characterization of clonogenic multiple myeloma cells. Blood 103:2332–2336PubMedCentralPubMedCrossRefGoogle Scholar
  35. Matthews DC et al (1995) Development of a marrow transplantation regimen for acute leukemia using targeted haematopoietic irradiation delivered by I-131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122–1131PubMedGoogle Scholar
  36. Matthews DC et al (1999) Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94:1237–1247PubMedGoogle Scholar
  37. Mulford D.A., et al. (2005) The promise of targeted [alpha]-particle therapy. J Nucl Med 46(Suppl1):199–204Google Scholar
  38. Nademanee A et al (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896–2902PubMedCentralPubMedCrossRefGoogle Scholar
  39. Newland A (2002) Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol 76(suppl):253–258PubMedCrossRefGoogle Scholar
  40. Orchard KH et al. (2006) Targeted radiotherapy in haematopoietic stem cell transplantation: Results of a phase I trial using a yttrium-90 labelled anti-CD66 murine monoclonal antibody demonstrating consistent BM targeting. Bone Marrow Transplant 37(suppl):P45, O338Google Scholar
  41. Preudhomme C et al (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100(8):2717–2723PubMedCrossRefGoogle Scholar
  42. Ratai R et al (2008) Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15 s) on blast cells of acute leukemias. Int J Hematol 87(2):137–143CrossRefGoogle Scholar
  43. Reske SN, Bunjes D, Buchmann I, Seitz U, Glatting G, Neumaier B, Kotzerke J, Buck A, Martin H, Döhner H, Bergmann L (2001) Eur J Nucl Med 28(7):807–815Google Scholar
  44. Richman CM et al (2005) High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 11:5920–5927PubMedCrossRefGoogle Scholar
  45. Ringhoffer M et al (2005) 188Re or 90Y—labeled anti—CD66 antibody as part of a dose—reduced conditioning regimen for patients with acute leukemia or myelodysplastic syndrome over the age of 55: results of a phase I—II study. Brit J Haematol 130:604–613CrossRefGoogle Scholar
  46. Santos GW et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and and cyclophosphamide regimen. N Engl J Med 309:1347–1353PubMedCrossRefGoogle Scholar
  47. Scheinberg DA et al (1989) Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 3:440–445PubMedGoogle Scholar
  48. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, et al (1993) J Clin Oncol 11(2):294–303Google Scholar
  49. Valcarcel D et al. (2007) Sustained remissions of high-risk acute myeloid leukaemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26:577 [Epub ahead of print]Google Scholar
  50. Vardiman JW et al (2002) The world health organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292–2302PubMedCrossRefGoogle Scholar
  51. Wheatley K et al (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 107(1):69–79PubMedCrossRefGoogle Scholar
  52. Witherspoon RP et al (2001) Haematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 19:2134–2141PubMedGoogle Scholar
  53. Zenz T et al (2006) Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. J Nucl Med 47:278–286PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Head of the Department of Nuclear MedicineUniversity Hospital Schleswig–HolsteinLübeckGermany

Personalised recommendations